{"id":178,"date":"2019-01-29T15:52:44","date_gmt":"2019-01-29T06:52:44","guid":{"rendered":"https:\/\/www.den.hokudai.ac.jp\/vascular-biol-pathol-test\/?page_id=178"},"modified":"2022-01-14T15:08:42","modified_gmt":"2022-01-14T06:08:42","slug":"publications2011","status":"publish","type":"page","link":"https:\/\/www.den.hokudai.ac.jp\/vascular-biol-pathol\/publications\/publications2011\/","title":{"rendered":"2011"},"content":{"rendered":"

\u7dcf\u8aac\u30fb\u8457\u66f8\uff08\u65e5\u672c\u8a9e\uff09<\/h4>\n
    \n
  1. \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u4f50\u85e4\u9756\u53f2, \u68ee\u7530\u80b2\u7537, \u9ad8\u5009\u4f38\u5e78, \u5c0f\u5ba4\u4e00\u6210\u76e3\u4fee, \u65e5\u672c\u8840\u7ba1\u751f\u7269\u533b\u5b66\u4f1a\u7de8\u300c\u8840\u7ba1\u751f\u7269\u533b\u5b66\u4e8b\u5178\u300d, \u201cVascular mimicry\u201d, \u201c\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u201d, \u671d\u5009\u66f8\u5e97, 206-209, 2011<\/li>\n<\/ol>\n

    \u82f1\u6587\u7dcf\u8aac<\/h4>\n
      \n
    1. *Hida K<\/u>, Kawamoto T, Ohga N, Akiyama K, Hida Y, Shindoh M: Altered angiogenesis in the tumor microenvironment, Pathol Int,\u00a0<\/em><\/strong>61(11), 630-637, 2011<\/li>\n<\/ol>\n

      \u82f1\u8a9e\u8ad6\u6587<\/h4>\n
        \n
      1. Kibria G, Hatakeyama H, Ohga N, Hida K<\/u>, Harashima H: Dual-ligand modification of PEGylated liposomes shows better cell selectivity and efficient gene delivery, J Controlled Release<\/em><\/strong>, 153(2), 141-148, 2011<\/li>\n
      2. Muraki C \u00a7<\/strong>, Ohga N \u00a7<\/strong>,Hida Y, Nishihara H, Kato Y, Tsuchiya K, Matsuda K, Totsuka Y, Shindoh M and *Hida K<\/u>: Cyclooxygenase- 2 inhibition causes antiangiogenic effects on tumor endothelial and vascular progenitor cells,\u00a0Int J Cancer,<\/em><\/strong>130(1), 59-72, 2011<\/li>\n
      3. Kurosu T, Ohga N, Hida Y, Maishi N, Akiyama K, Kakuguchi W, Kuroshima T, Kondo M, Akino T, Totsuka Y, Shindoh M, Higashino F and *<\/strong>Hida K<\/u>.\u00a7<\/strong>: HuR keeps an angiogenic switch on by stabilizing mRNA of VEGF and COX-2 in tumor endothelium,Br J<\/em><\/strong>\u00a0Cancer<\/em><\/strong>, 104(5), 819-829, 2011\u00a0\u3014PDF\u3015<\/a><\/li>\n
      4. Nitta Y, Hida K<\/u>, Kitamura T, Higashino F, Ohga N, Fukushima K, Shindoh M: Phenotype of tumor lymphatic vessels is a prognostic factor in human tongue squamous cell carcinoma, Oncol Lett<\/em><\/strong>, 2(1), 79-83, 2011<\/li>\n<\/ol>\n

        \u62db\u5f85\u8b1b\u6f14<\/h4>\n
          \n
        1. \u6a0b\u7530\u4eac\u5b50<\/u>\uff1aRecent Advance in Tumor Angiogenesis 2011, \u201c\u816b\u760d\u8840\u7ba1\u306e\u591a\u69d8\u6027\u3068\u304c\u3093\u306e\u8ee2\u79fb\u201d, 2011.12.3\uff08\u6d5c\u677e\uff09<\/li>\n
        2. \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u51fd\u9928Basic Cancer Forum, \u201c\u816b\u760d\u8840\u7ba1\u65b0\u751f\u963b\u5bb3\u7642\u6cd5\u306b\u304a\u3051\u308b\u65b0\u305f\u306a\u5c40\u9762-Lesson from Basic research\u201d, 2011.11.24\uff08\u51fd\u9928\uff09<\/li>\n
        3. \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a<\/strong>\u5e73\u621023\u5e74\u5ea6\u907a\u4f1d\u5b50\u75c5\u5236\u5fa1\u7814\u7a76\u6240\u5171\u540c\u7814\u7a76\u96c6\u4f1a, \u201c\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u7570\u5e38\u6027\u304c\u3082\u305f\u3089\u3059\u304c\u3093\u6cbb\u7642\u3078\u306e\u5f71\u97ff\u201d, 2011.9.6\uff08\u672d\u5e4c\uff09<\/li>\n
        4. \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a<\/strong>\u5927\u962a\u6b6f\u79d1\u5927\u5b66\u5927\u5b66\u966250\u5468\u5e74\u8a18\u5ff5\u8b1b\u6f14\u4f1a, \u201c\u816b\u760d\u8840\u7ba1\u7279\u7570\u6027\u306e\u89e3\u660e\u3068\u65b0\u305f\u306a\u8840\u7ba1\u65b0\u751f\u963b\u5bb3\u7642\u6cd5\u3078\u306e\u5fdc\u7528\u201d, 2011.9.2\uff08\u5927\u962a\uff09<\/li>\n
        5. Hida K<\/u>\uff1a<\/strong>\u201cA New Insights into Tumor endothelial cell\u201d, The 5th Meeting of Asian Society of Oral and Maxillofacial Pathology, 2011.8.24\uff08Fukuoka, Japan\uff09<\/li>\n
        6. \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a<\/strong>\u7b2c63\u56de\u65e5\u672c\u7d30\u80de\u751f\u7269\u5b66\u4f1a\u5927\u4f1a, \u201c\u8840\u7ba1\u306e\u591a\u69d8\u6027\uff5e\u7d44\u7e54\u767a\u751f\u304b\u3089\u75be\u60a3\u306b\u304a\u3051\u308b\u30c0\u30a4\u30ca\u30df\u30af\u30b9\u201d, 2011.6.29\uff08\u672d\u5e4c\uff09<\/li>\n
        7. \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a<\/strong>ACCEL in Hokkaido\uff5eNSCLC\u306b\u5bfe\u3059\u308b\u30a2\u30d0\u30b9\u30c1\u30f3\u306e\u6cbb\u7642\u6226\u7565\uff5e, \u201c\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u7279\u7570\u6027\u3068\u305d\u306e\u5236\u5fa1\u201d, 2011.6.18\uff08\u672d\u5e4c\uff09<\/li>\n
        8. \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a<\/strong>\u7b2c27\u56de\u65e5\u672cDDS\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, \u201c\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u591a\u69d8\u306a\u751f\u7269\u50cf\u201d, 2011.6.9\uff08\u6771\u4eac\uff09<\/li>\n
        9. \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a<\/strong>\u9ad8\u77e5\u5927\u5b66\u533b\u5b66\u90e8\u6b6f\u79d1\u53e3\u8154\u5916\u79d1\u5b66\u8b1b\u5ea7\u30bb\u30df\u30ca\u30fc, \u201c\u304c\u3093\u7d44\u7e54\u306b\u304a\u3051\u308b\u8840\u7ba1\u306e\u7279\u7570\u6027\u306e\u89e3\u660e\u3068\u65b0\u305f\u306a\u8840\u7ba1\u65b0\u751f\u963b\u5bb3\u7642\u6cd5\u3078\u306e\u5fdc\u7528\u201d, 2011.6.3\uff08\u9ad8\u77e5\uff09<\/li>\n
        10. \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a<\/strong>\u7b2c100\u56de\u65e5\u672c\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a\u30b3\u30f3\u30d1\u30cb\u30aa\u30f3\u30df\u30fc\u30c6\u30a3\u30f3\u30b04\u300c\u53e3\u8154\u764c\u306e\u6d78\u6f64\uff1a\u5916\u79d1\u75c5\u7406\u3068\u5206\u5b50\u75c5\u7406\u306e\u67b6\u3051\u6a4b\u300d, \u201c\u764c\u9593\u8cea\u306e\u7570\u5e38, \u3068\u304f\u306b\u816b\u760d\u8840\u7ba1\u306e\u7279\u6027\u3068\u6d78\u6f64\u3068\u306e\u95a2\u9023\u6027\u201d, 2011.5.1\uff08\u6771\u4eac\uff09<\/li>\n
        11. \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a<\/strong>\u7b2c\uff19\u56de\u53e3\u8154\u533b\u79d1\u5b66\u30d5\u30ed\u30f3\u30c6\u30a3\u30a2\u5b66\u8853\u96c6\u4f1a, \u304c\u3093\u5fae\u5c0f\u74b0\u5883\u5185\u306b\u304a\u3051\u308b\u816b\u760d\uff0d\u8840\u7ba1\u306e\u76f8\u4e92\u4f5c\u7528, 2011.3.5\uff08\u798f\u5ca1\uff09<\/li>\n
        12. \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a<\/strong>The 8th Annual Meeting for the Japanese Association for Cancer and Hypoxia Research, \u201c\u4f4e\u9178\u7d20\u74b0\u5883\u306b\u304a\u3051\u308b\u816b\u760d\u8840\u7ba1\u30c0\u30a4\u30ca\u30df\u30af\u30b9\u201d, 2011.1.29-30\uff08\u672d\u5e4c\uff09<\/li>\n<\/ol>\n

          \u56fd\u969b\u5b66\u4f1a\u767a\u8868<\/strong><\/h4>\n
            \n
          1. Ohga N, Ishikawa S, Hida Y, Akiyama K, Kitayama K, Kondoh M, Maishi N, Kawamoto T, Ohsawa T, Yamamoto K, Shindoh M, Hida K<\/u>\uff1aComparative characterization of tumor endothelial cells isolated from highly and low metastatic tumors, The 5th Meeting of Asian Society of Oral and Maxillofacial Pathology,\u201cA New Insights into Tumor endothelial cell\u201d, 2011.8.24\uff08Fukuoka,\u3000Japan\uff09(Invited Speaker)<\/li>\n
          2. Maishi N, Ohga N, Hida Y, Ohba Y, Kawamoto T, Akiyama K, Kitayama K, Kondoh M, Ohsawa T, Yamamoto K, Inoue N, Shindoh M, Hida K<\/u>: Analysis of interaction between tumor endothelial cells and tumor cells, AACR 102nd ANNUAL MEETING 2011, 2011.4. 2-6, Orlando, Florida<\/li>\n
          3. Kondoh M, Ohga N, Kitayama K, Akiyama K, Maishi N, Kawamoto T, Ohsawa T, Yamamoto K, Shindoh M, Inoue N, Hida Y, Hida K<\/u>: Gene expression analysis of circulating endothelial cells in cancer patients, AACR 102nd ANNUAL MEETING 2011, 2011.4. 2-6, Orlando, Florida<\/li>\n<\/ol>\n

            \u56fd\u5185\u5b66\u4f1a\u767a\u8868<\/strong><\/h4>\n
              \n
            1. \u5c71\u672c\u548c\u5e78\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u5ddd\u672c\u6cf0\u8f14\uff0c\u5317\u5c71\u548c\u5b50\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u5927\u6fa4\u5d07\u5b8f\uff0c\u8fd1\u85e4\u7f8e\u5f25\u5b50\uff0c\u52a0\u8cc0\u57fa\u77e5\u4e09\uff0c\u5e73\u91ce\u3000\u8061, \u7be0\u539f\u4fe1\u96c4\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\u00a0: Biglycan is an angiogenic factor stimulating cell migration of tumor endothelium, \u7b2c19\u56de\u65e5\u672c\u8840\u7ba1\u751f\u7269\u533b\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2011.12.8-10\uff08\u6771\u4eac\uff09<\/li>\n
            2. \u5927\u8cc0\u5247\u5b5d\uff0c\u77f3\u5ddd\u4fee\u5e73\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u5ddd\u672c\u6cf0\u8f14\uff0c\u5b9a\u672c\u572d\u5f18\uff0c\u8fd1\u85e4\u7f8e\u5f25\u5b50\uff0c\u5927\u6fa4\u5d07\u5b8f\uff0c\u5c71\u672c\u548c\u5e78\uff0c\u5927\u6751\u3000\u77b3\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\u00a0: Heterogeneity of Tumor Endothelial Cells:Comparison between Tumor Endothelial Cells Isolated from Highly Metastatic and Low Metastatic Tumors, \u7b2c19\u56de\u65e5\u672c\u8840\u7ba1\u751f\u7269\u533b\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2011.12.8-10\uff08\u6771\u4eac\uff09<\/li>\n
            3. \u5ddd\u672c\u6cf0\u8f14\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u5927\u6fa4\u5d07\u5b8f\uff0c\u5c71\u672c\u548c\u5e78\uff0c\u8fd1\u85e4\u7f8e\u5f25\u5b50\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>: Tumor-derived Microvesicles Promote Cell Motility and Tubeformation via Endocytosis in Endothelial Cells, \u7b2c19\u56de\u65e5\u672c\u8840\u7ba1\u751f\u7269\u533b\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2011.12.8-10\uff08\u6771\u4eac\uff09<\/li>\n
            4. \u5927\u6fa4\u5d07\u5b8f\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u5317\u5c71\u548c\u5b50\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u5ddd\u672c\u6cf0\u8f14\uff0c\u8fd1\u85e4\u7f8e\u5f25\u5b50\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u5c71\u672c\u548c\u5e78\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u7be0\u539f\u4fe1\u96c4\uff0c\u91ce\u3005\u6751\u514b\u4e5f\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>: The role of Lysyl oxidase on abnormal phenotypes of tumor endothelial cells, \u7b2c19\u56de\u65e5\u672c\u8840\u7ba1\u751f\u7269\u533b\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2011.12.8-10\uff08\u6771\u4eac\uff09<\/li>\n
            5. \u79cb\u5c71\u5ee3\u8f14\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u5ddd\u672c\u6cf0\u8f14\uff0c\u5b9a\u672c\u572d\u5f18\uff0c \u77f3\u5ddd\u4fee\u5e73\uff0c\u9593\u77f3\u5948\u6e56\uff0c \u79cb\u91ce\u6587\u81e3, \u8fd1\u85e4\u7f8e\u5f25\u5b50\uff0c\u5927\u6fa4\u5d07\u5b8f\uff0c\u5c71\u672c\u548c\u5e78\uff0c\u5927\u6751\u3000\u77b3\uff0c\u677e\u7530\u3000\u5f69\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>: Tumor endothelial cells aquire drug resistance by MDR1 upregulation via VEGF signaling in tumor microenvironment, \u7b2c19\u56de\u65e5\u672c\u8840\u7ba1\u751f\u7269\u533b\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2011.12.8-10\uff08\u6771\u4eac\uff09<\/li>\n
            6. \u5927\u8cc0\u5247\u5b5d, \u77f3\u5ddd\u4fee\u5e73, \u6a0b\u7530\u6cf0\u6d69, \u79cb\u5c71\u5ee3\u8f14, \u9593\u77f3\u5948\u6e56, \u8fd1\u85e4\u7f8e\u5f25\u5b50, \u5ddd\u672c\u6cf0\u8f14, \u9032\u85e4\u6b63\u4fe1, \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u8ee2\u79fb\u80fd\u306e\u7570\u306a\u308b\u816b\u760d\u304b\u3089\u5206\u96e2\u3055\u308c\u305f\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u6bd4\u8f03\u89e3\u6790, \u816b\u760d\u5fae\u5c0f\u74b0\u5883\u306b\u304a\u3051\u308b\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7570\u5e38\u6027\u306e\u7372\u5f97, \u7b2c70\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a, 2011.10.5\uff08\u540d\u53e4\u5c4b\uff09<\/li>\n
            7. \u9593\u77f3\u5948\u6e56, \u5927\u8cc0\u5247\u5b5d, \u6a0b\u7530\u6cf0\u6d69, \u5927\u5834\u96c4\u4ecb, \u6d5c\u7530\u6df3\u4e00, \u79cb\u5c71\u5ee3\u8f14, \u5c71\u672c\u548c\u5e78, \u5927\u6fa4\u5d07\u5b8f, \u8fd1\u85e4\u7f8e\u5f25\u5b50, \u5ddd\u672c\u6cf0\u8f14, \u9032\u85e4\u6b63\u4fe1, \u4e95\u4e0a\u8fb2\u592b\u7537, \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u3068\u304c\u3093\u8ee2\u79fb\u3068\u306e\u76f8\u4e92\u4f5c\u7528\u89e3\u6790, \u7b2c70\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a, 2011.10.5\uff08\u540d\u53e4\u5c4b\uff09<\/li>\n
            8. \u5927\u6fa4\u5d07\u5b8f, \u5927\u8cc0\u5247\u5b5d, \u5317\u5c71\u548c\u5b50, \u6a0b\u7530\u6cf0\u6d69, \u5ddd\u672c\u6cf0\u8f14, \u8fd1\u85e4\u7f8e\u5f25\u5b50, \u9593\u77f3\u5948\u6e56, \u5c71\u672c\u548c\u5e78, \u79cb\u5c71\u5ee3\u8f14, \u7be0\u539f\u4fe1\u96c4, \u91ce\u3005\u6751\u514b\u4e5f, \u9032\u85e4\u6b63\u4fe1, \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u306b\u304a\u3051\u308bLysyl oxidase\u306e\u6a5f\u80fd\u89e3\u6790, \u7b2c70\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a, 2011.10.5\uff08\u540d\u53e4\u5c4b\uff09<\/li>\n
            9. \u6a0b\u7530\u4eac\u5b50,<\/u> \u5927\u8cc0\u5247\u5b5d, \u79cb\u5c71\u5ee3\u8f14, \u6a0b\u7530\u6cf0\u6d69\uff1a\u816b\u760d\u5fae\u5c0f\u74b0\u5883\u306b\u304a\u3051\u308b\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7570\u5e38\u6027\u306e\u7372\u5f97, \u7b2c70\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a, 2011.10.4\uff08\u540d\u53e4\u5c4b\uff09<\/li>\n
            10. \u79cb\u5c71\u5ee3\u8f14, \u5927\u8cc0\u5247\u5b5d, \u6a0b\u7530\u6cf0\u6d69, \u5ddd\u672c\u6cf0\u8f14, \u5b9a\u672c\u572d\u5f18, \u77f3\u5ddd\u4fee\u5e73, \u8fd1\u85e4\u7f8e\u5f25\u5b50, \u9593\u77f3\u5948\u6e56, \u5927\u6fa4\u5d07\u5b8f, \u5c71\u672c\u548c\u5e78, \u9032\u85e4\u6b63\u4fe1, \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u764c\u7d30\u80de\u57f9\u990a\u4e0a\u6e05\u306b\u3088\u308b\u6b63\u5e38\u8840\u7ba1\u5185\u76ae\u306e\u85ac\u5264\u62b5\u6297\u6027\u306e\u7372\u5f97, \u7b2c70\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a, 2011.10.3\uff08\u540d\u53e4\u5c4b\uff09<\/li>\n
            11. \u8fd1\u85e4\u7f8e\u5f25\u5b50, \u5927\u8cc0\u5247\u5b5d, \u79cb\u5c71\u5ee3\u8f14, \u9593\u77f3\u5948\u6e56, \u5ddd\u672c\u6cf0\u8f14, \u5927\u6fa4\u5d07\u5b8f, \u5c71\u672c\u548c\u5e78, \u5927\u6751\u00a0 \u77b3, \u6a0b\u7530\u6cf0\u6d69, \u9032\u85e4\u6b63\u4fe1, \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u4f4e\u9178\u7d20\u74b0\u5883\u304c\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306b\u53ca\u307c\u3059\u5f71\u97ff, \u7b2c70\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a, 2011.10.3\uff08\u540d\u53e4\u5c4b\uff09<\/li>\n
            12. \u5c71\u672c\u548c\u5e78, \u5927\u8cc0\u5247\u5b5d, \u6a0b\u7530\u6cf0\u6d69, \u5317\u5c71\u548c\u5b50, \u9593\u77f3\u5948\u6e56, \u5927\u6fa4\u5d07\u5b8f, \u5ddd\u672c\u6cf0\u8f14, \u8fd1\u85e4\u7f8e\u5f25\u5b50, \u79cb\u5c71\u5ee3\u8f14, \u52a0\u8cc0\u57fa\u77e5\u4e09, \u5e73\u91ce\u00a0 \u8061, \u9032\u85e4\u6b63\u4fe1, \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u306b\u304a\u3051\u308bBiglycan\u306e\u6a5f\u80fd\u89e3\u6790, \u7b2c70\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a, 2011.10.3\uff08\u540d\u53e4\u5c4b\uff09<\/li>\n
            13. \u5ddd\u672c\u6cf0\u8f14, \u5927\u8cc0\u5247\u5b5d, \u79cb\u5c71\u5ee3\u8f14, \u9593\u77f3\u5948\u6e56, \u5927\u6fa4\u5d07\u5b8f, \u5c71\u672c\u548c\u5e78, \u8fd1\u85e4\u7f8e\u5f25\u5b50, \u9032\u85e4\u6b63\u4fe1, \u6a0b\u7530\u6cf0\u6d69, \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u7531\u6765microvesicles\u304c\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u904b\u52d5\u80fd\u3068\u7ba1\u8154\u5f62\u6210\u80fd\u3092\u4ea2\u9032\u3055\u305b\u308b, \u7b2c70\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a, 2011.10.3\uff08\u540d\u53e4\u5c4b\uff09<\/li>\n
            14. \u9593\u77f3\u5948\u6e56, \u79cb\u5c71\u5ee3\u8f14, \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u3068\u304c\u3093\u8ee2\u79fb\u3068\u306e\u76f8\u4e92\u4f5c\u7528\u89e3\u6790, \u7b2c53\u56de\u6b6f\u79d1\u57fa\u790e\u533b\u5b66\u4f1a\u5b66\u8853\u5927\u4f1a\u30fb\u7dcf\u4f1a, 2011.10.1\uff08\u5c90\u961c\uff09<\/li>\n
            15. \u79cb\u5c71\u5ee3\u8f14, \u9593\u77f3\u5948\u6e56,\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u7d30\u80de\u7531\u6765\u56e0\u5b50\u306b\u3088\u308b\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u85ac\u5264\u62b5\u6297\u6027\u7372\u5f97\u306b\u3064\u3044\u3066,\u7b2c53\u56de\u6b6f\u79d1\u57fa\u790e\u533b\u5b66\u4f1a\u5b66\u8853\u5927\u4f1a\u30fb\u7dcf\u4f1a, 2011.10.1\uff08\u5c90\u961c\uff09<\/li>\n
            16. \u5ddd\u672c\u6cf0\u8f14, \u5927\u8cc0\u5247\u5b5d, \u79cb\u5c71\u5ee3\u8f14, \u8fd1\u85e4\u7f8e\u5f25\u5b50, \u9593\u77f3\u5948\u6e56, \u5927\u6fa4\u5d07\u5b8f, \u5c71\u672c\u548c\u5e78, \u6a0b\u7530\u6cf0\u6d69, \u9032\u85e4\u6b63\u4fe1, \u6a0b\u7530\u4eac\u5b50<\/u>\uff1aTumor-derived microvesicles\u304c\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306emotility\u3068Akt\u306e\u6d3b\u6027\u5316\u306b\u5bc4\u4e0e\u3059\u308b, \u7b2c91\u56de\u5317\u6d77\u9053\u533b\u5b66\u5927\u4f1a\u7dcf\u4f1a\uff08\u7b2c104\u56de\u5317\u6d77\u9053\u764c\u8ac7\u8a71\u4f1a\u4f8b\u4f1a\u3000\u816b\u760d\u5206\u79d1\u4f1a\uff09, 2011.9.17\uff08\u672d\u5e4c\uff09<\/li>\n
            17. \u5c71\u672c\u548c\u5e78, \u5927\u8cc0\u5247\u5b5d, \u6a0b\u7530\u6cf0\u6d69, \u9593\u77f3\u5948\u6e56, \u5ddd\u672c\u6cf0\u8f14, \u79cb\u5c71\u5ee3\u8f14, \u5927\u6fa4\u5d07\u5b8f, \u8fd1\u85e4\u7f8e\u5f25\u5b50, \u5927\u6751\u77b3, \u6a0b\u7530\u4eac\u5b50<\/u>\uff1aBiglycan\u306f\u816b\u760d\u8840\u7ba1\u5185\u76ae\u306e\u904a\u8d70\u3092\u4fc3\u9032\u3059\u308b, \u7b2c91\u56de\u5317\u6d77\u9053\u533b\u5b66\u5927\u4f1a\u7dcf\u4f1a\uff08\u7b2c104\u56de\u5317\u6d77\u9053\u764c\u8ac7\u8a71\u4f1a\u4f8b\u4f1a\u3000\u816b\u760d\u5206\u79d1\u4f1a\uff09, 2011.9.17\uff08\u672d\u5e4c\uff09<\/li>\n
            18. \u5927\u8cc0\u5247\u5b5d, \u77f3\u5ddd\u4fee\u5e73, \u6a0b\u7530\u6cf0\u6d69, \u79cb\u5c71\u5ee3\u8f14, \u9593\u77f3\u5948\u6e56, \u5ddd\u672c\u6cf0\u8f14, \u8fd1\u85e4\u7f8e\u5f25\u5b50, \u9032\u85e4\u6b63\u4fe1, \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u8ee2\u79fb\u80fd\u306e\u7570\u306a\u308b\u816b\u760d\u7531\u6765\u306e\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u7279\u6027\u89e3\u6790, \u7b2c91\u56de\u5317\u6d77\u9053\u533b\u5b66\u5927\u4f1a\u7dcf\u4f1a\uff08\u7b2c104\u56de\u5317\u6d77\u9053\u764c\u8ac7\u8a71\u4f1a\u4f8b\u4f1a\u3000\u816b\u760d\u5206\u79d1\u4f1a\uff09, 2011.9.17\uff08\u672d\u5e4c\uff09<\/li>\n
            19. \u79cb\u5c71\u5ee3\u8f14, \u5927\u8cc0\u5247\u5b5d, \u6a0b\u7530\u6cf0\u6d69, \u5ddd\u672c\u6cf0\u8f14, \u5b9a\u672c\u572d\u5f18, \u77f3\u5ddd\u4fee\u5e73, \u8fd1\u85e4\u7f8e\u5f25\u5b50, \u9593\u77f3\u5948\u6e56, \u9032\u85e4\u6b63\u4fe1,\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u5fae\u5c0f\u74b0\u5883\u306b\u304a\u3051\u308bMDR1\u306e\u767a\u73fe\u4ea2\u9032\u3092\u4f34\u3063\u305f\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u85ac\u5264\u62b5\u6297\u6027\u7372\u5f97\u306b\u3064\u3044\u3066, \u7b2c91\u56de\u5317\u6d77\u9053\u533b\u5b66\u5927\u4f1a\u7dcf\u4f1a\uff08\u7b2c104\u56de\u5317\u6d77\u9053\u764c\u8ac7\u8a71\u4f1a\u4f8b\u4f1a\u3000\u816b\u760d\u5206\u79d1\u4f1a\uff09, 2011.9.17\uff08\u672d\u5e4c\uff09<\/li>\n
            20. \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u304c\u3093\u8ee2\u79fb\u306b\u95a2\u308f\u308b\u816b\u760d\u8840\u7ba1\u5185\u76ae\u306e\u7570\u5e38\u6027, \u7b2c20\u56de\u65e5\u672c\u304c\u3093\u8ee2\u79fb\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30fb\u7dcf\u4f1a, 2011.6.30\uff08\u6d5c\u677e\uff09<\/li>\n
            21. \u5927\u8cc0\u5247\u5b5d, \u77f3\u5ddd\u4fee\u5e73, \u6a0b\u7530\u6cf0\u6d69, \u9593\u77f3\u5948\u6e56, \u5ddd\u672c\u6cf0\u8f14, \u79cb\u5c71\u5ee3\u8f14, \u8fd1\u85e4\u7f8e\u5f25\u5b50, \u9032\u85e4\u6b63\u4fe1,\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u8ee2\u79fb\u80fd\u306e\u7570\u306a\u308b\u816b\u760d\u7531\u6765\u306e\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u7279\u6027\u89e3\u6790, \u7b2c20\u56de\u65e5\u672c\u304c\u3093\u8ee2\u79fb\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30fb\u7dcf\u4f1a, 2011.6.30\uff08\u6d5c\u677e\uff09<\/li>\n
            22. \u9593\u77f3\u5948\u6e56, \u5927\u8cc0\u5247\u5b5d, \u6a0b\u7530\u6cf0\u6d69, \u5927\u5834\u96c4\u4ecb, \u6d5c\u7530\u6df3\u4e00, \u79cb\u5c71\u5ee3\u8f14, \u5c71\u672c\u548c\u5e78, \u5927\u6fa4\u5d07\u5b8f, \u8fd1\u85e4\u7f8e\u5f25\u5b50, \u5ddd\u672c\u6cf0\u8f14, \u4e95\u4e0a\u8fb2\u592b\u7537, \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u3068\u304c\u3093\u8ee2\u79fb\u3068\u306e\u76f8\u4e92\u4f5c\u7528\u89e3\u6790, \u7b2c20\u56de\u65e5\u672c\u304c\u3093\u8ee2\u79fb\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30fb\u7dcf\u4f1a\u30012011.6.30\uff08\u6d5c\u677e\uff09<\/li>\n
            23. \u79cb\u5c71\u5ee3\u8f14\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u77f3\u5ddd\u4fee\u5e73\uff0c\u5b9a\u672c\u572d\u5f18\uff0c\u5ddd\u672c\u6cf0\u8f14\uff0c\u8fd1\u85e4\u7f8e\u5f25\u5b50\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u9ce5\u5c45\u3061\u3055\u307b\uff0c\u5317\u5c71\u548c\u5b50\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1aEndothelial cells acquire drug resistance by factors from tumor cells. \u7b2c63\u56de\u65e5\u672c\u7d30\u80de\u751f\u7269\u5b66\u4f1a\u5927\u4f1a\uff0c2011.6.29\uff08\u672d\u5e4c\uff09<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

              \u7dcf\u8aac\u30fb\u8457\u66f8\uff08\u65e5\u672c\u8a9e\uff09 \u6a0b\u7530\u4eac\u5b50\uff1a\u4f50\u85e4\u9756\u53f2, \u68ee\u7530\u80b2\u7537, \u9ad8\u5009\u4f38\u5e78, \u5c0f\u5ba4\u4e00\u6210\u76e3\u4fee, \u65e5\u672c\u8840\u7ba1\u751f\u7269\u533b\u5b66\u4f1a\u7de8\u300c\u8840\u7ba1\u751f\u7269\u533b\u5b66\u4e8b\u5178\u300d, \u201cVascular mimicry\u201d, \u201c\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u201d, \u671d\u5009\u66f8\u5e97, 206-209, 2011 \u82f1\u6587\u7dcf\u8aac *Hida K, Kawamoto T, Ohga N, Akiyama K, Hida Y, Shindoh M: Altered angiogenesis…\u7d9a\u304d\u3092\u8aad\u3080<\/a><\/p>\n","protected":false},"author":3,"featured_media":0,"parent":18,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"publications.php","meta":{"footnotes":""},"class_list":["post-178","page","type-page","status-publish","hentry"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.den.hokudai.ac.jp\/vascular-biol-pathol\/wp-json\/wp\/v2\/pages\/178","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.den.hokudai.ac.jp\/vascular-biol-pathol\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.den.hokudai.ac.jp\/vascular-biol-pathol\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.den.hokudai.ac.jp\/vascular-biol-pathol\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.den.hokudai.ac.jp\/vascular-biol-pathol\/wp-json\/wp\/v2\/comments?post=178"}],"version-history":[{"count":7,"href":"https:\/\/www.den.hokudai.ac.jp\/vascular-biol-pathol\/wp-json\/wp\/v2\/pages\/178\/revisions"}],"predecessor-version":[{"id":869,"href":"https:\/\/www.den.hokudai.ac.jp\/vascular-biol-pathol\/wp-json\/wp\/v2\/pages\/178\/revisions\/869"}],"up":[{"embeddable":true,"href":"https:\/\/www.den.hokudai.ac.jp\/vascular-biol-pathol\/wp-json\/wp\/v2\/pages\/18"}],"wp:attachment":[{"href":"https:\/\/www.den.hokudai.ac.jp\/vascular-biol-pathol\/wp-json\/wp\/v2\/media?parent=178"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}